NICI-UK-PILOT -v1
Research type
Research Study
Full title
Non-Invasive Chemistry Imaging in the human body: 7T metabolic MRI pilot study in patients with liver metastases
IRAS ID
302116
Contact name
Elizabeth Smyth
Contact email
Sponsor organisation
Cambridge University Hospitals
Duration of Study in the UK
0 years, 11 months, 8 days
Research summary
This study aims to test a new method of monitoring the response of tumours to chemotherapy using ultra-high field (7T) metabolic MRI.
Our technique measures metabolites that are critical to the formation of new cells by a tumour. We expect that the level of these metabolites will change within days after patients start an effective chemotherapy regime, whereas we expect less (or no) change in cases where the chemotherapy regime is not benefitting a specific patient.
We wish to test this approach through metabolic MRI scans of patients with gastrointestinal cancer who have metastases (secondary growths) in their liver.
Patients who agree to participate in our study will be invited for a 7T metabolic MRI scan before they commence chemotherapy and a second scan a few weeks afterwards. We will also ask for consent to check their medical records to follow what happens to their cancer and to compare to standard computed tomography images that are used to track the size of liver metastases (secondary tumours).REC name
South Central - Oxford A Research Ethics Committee
REC reference
22/SC/0211
Date of REC Opinion
22 Jun 2022
REC opinion
Favourable Opinion